Schrodinger, Inc. ( (SDGR) ) has released its Q2 earnings. Here is a breakdown of the information Schrodinger, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Schrödinger, Inc. is a company specializing in computational technology for molecular discovery, primarily serving the biotechnology and pharmaceutical sectors with a unique platform that accelerates drug development and materials design.
In its second quarter of 2025, Schrödinger reported a total revenue of $54.8 million, marking a 16% increase from the previous year, while software revenue rose by 15% to $40.5 million. The company also maintained its full-year revenue growth guidance and reduced its operating expense guidance.
Key financial highlights include a significant increase in drug discovery revenue to $14.2 million, a decrease in operating expenses to $79.1 million, and a reduction in net loss to $43.2 million from $54.0 million in the same quarter of the previous year. The company also achieved a milestone with its MALT1 inhibitor, SGR-1505, which showed promising initial Phase 1 data and received FDA Fast Track Designation.
Looking ahead, Schrödinger remains optimistic about its financial outlook for 2025, expecting software revenue growth between 10% and 15%, and drug discovery revenue between $45 million and $50 million. The company continues to focus on strategic opportunities to advance its clinical programs and enhance its computational platform.